{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T08:17:06Z","timestamp":1768637826714,"version":"3.49.0"},"reference-count":21,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T00:00:00Z","timestamp":1638662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Comprehension regarding immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is limited, and the durability of immune responses after vaccination is currently unknown. Several studies have reported on the antibody response in fully vaccinated individuals with a limited follow-up of the participants, i.e., below 7 months. Materials and Methods: The antibody response to complete vaccination with the BNT162b2 mRNA COVID-19 vaccine was assessed monthly, for 7 months, in 92 healthcare workers, between February 26 and September 26, 2021. The SARS-CoV-2 anti-spike protein IgG (IgGS) antibody was detected using the SARS-CoV-2 IgG II Quant assay (Abbott, Diagnostics Division, Sligo, Ireland), a chemiluminescent microparticle immunoassay (CMIA) with a sensitivity of 98.1% and specificity of 99.6%. Participants were divided into two groups, one for individuals previously infected with SARS-CoV-2 and the other for individuals without previous infection. Results: The median IgGS titers decreased monthly both in previously infected individuals and in the uninfected group. Previously infected individuals had significantly higher median titers of IgGS compared with previously uninfected subjects at all seven time points after complete vaccination (p &lt; 0.001). Conclusions: Seven months after vaccination, the median IgGS titer had decreased by more than 92% both in individuals previously infected with SARS-CoV-2 and in uninfected individuals. However, IgGS antibodies were still detected in all study participants and persisted throughout the 7 months after the second dose of the vaccine. Further studies should be conducted to monitor the antibody response to the BNT162b2 mRNA vaccine beyond 7 months, to assess the need for a new booster dose in order to extend the duration and amplitude of the specific immune response.<\/jats:p>","DOI":"10.3390\/medicina57121330","type":"journal-article","created":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T21:01:45Z","timestamp":1638738105000},"page":"1330","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1094-3729","authenticated-orcid":false,"given":"Tudor Rares","family":"Olariu","sequence":"first","affiliation":[{"name":"Discipline of Parasitology, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinical Laboratory, Municipal Clinical Emergency Teaching Hospital, 300041 Timisoara, Romania"},{"name":"Center for Diagnosis and Study of Parasitic Diseases, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorin","family":"Ursoniu","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Systems Medicine, Department of Functional Sciences, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iosif","family":"Marincu","sequence":"additional","affiliation":[{"name":"Discipline of Parasitology, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-1934","authenticated-orcid":false,"given":"Maria Alina","family":"Lupu","sequence":"additional","affiliation":[{"name":"Discipline of Parasitology, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Center for Diagnosis and Study of Parasitic Diseases, Department of Infectious Disease, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania"},{"name":"Clinical Laboratory, Institute of Cardiovascular Diseases, 300041 Timisoara, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"Pfizer (2021, October 09). Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048). Vaccines and Related Biological Products Advisory Committee Briefing Document, Available online: https:\/\/www.fda.gov\/media\/144246\/download."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.15585\/mmwr.mm6950e2","article-title":"The Advisory Committee on Immunization Practices\u2019 Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine\u2014United States, December 2020","volume":"69","author":"Oliver","year":"2020","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e0024721","DOI":"10.1128\/Spectrum.00247-21","article-title":"Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five Quantitative Assays","volume":"9","author":"Perkmann","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: Review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"ref_6","unstructured":"U.S. Food and Drug Administration (2021, October 09). Vaccines and Related Biological Products Advisory Committee Briefing Document. BNT162b2 [COMIRNATY (COVID-19 Vaccine, mRNA)]. Evaluation of a Booster Dose (Third Dose), Available online: https:\/\/www.fda.gov\/media\/152161\/download."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/22221751.2021.1953403","article-title":"Antibody titres decline 3-month post-vaccination with BNT162b2","volume":"10","author":"Favresse","year":"2021","journal-title":"Emerg. Microbes Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1351.e5","DOI":"10.1016\/j.cmi.2021.05.004","article-title":"Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2)","volume":"27","author":"Favresse","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat. Med."},{"key":"ref_10","unstructured":"U.S. Food and Drug Administration (2021, October 09). EUA Authorized Serology Test Performance, Available online: https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/eua-authorized-serology-test-performance."},{"key":"ref_11","unstructured":"U.S. Food and Drug Administration (2021, October 09). FTD\u2122 SARS-CoV-2, Available online: https:\/\/www.fda.gov\/media\/137690\/download."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tretyn, A., Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Sandomierz, D., Dejewska, J., Ciechanowska, K., Jarkiewicz-Tretyn, A., Koper, W., and Pa\u0142gan, K. (2021). Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination. Cells, 10.","DOI":"10.21203\/rs.3.rs-388040\/v3"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(21)00502-X","article-title":"Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine","volume":"397","author":"Prendecki","year":"2021","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1001\/jama.2021.6042","article-title":"Spike Antibody Levels of Nursing Home Residents With or Without Prior COVID-19 3 Weeks After a Single BNT162b2 Vaccine Dose","volume":"325","author":"Blain","year":"2021","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eabf4063","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"784.e1","DOI":"10.1016\/j.cmi.2021.01.005","article-title":"Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: A prospective longitudinal study","volume":"27","author":"Meyer","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ijid.2021.04.078","article-title":"Dynamic changes and prevalence of SARS-CoV-2 IgG\/IgM antibodies: Analysis of multiple factors","volume":"108","author":"Luo","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","article-title":"Neutralizing antibody titers in SARS-CoV-2 infections","volume":"12","author":"Lau","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.ajic.2021.02.012","article-title":"Impact of the influenza vaccine on COVID-19 infection rates and severity","volume":"49","author":"Conlon","year":"2021","journal-title":"Am. J. Infect. Control."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11357-021-00323-3","article-title":"The impact of immuno-aging on SARS-CoV-2 vaccine development","volume":"43","author":"Connors","year":"2021","journal-title":"Geroscience"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/12\/1330\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:39:54Z","timestamp":1760168394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/12\/1330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,5]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["medicina57121330"],"URL":"https:\/\/doi.org\/10.3390\/medicina57121330","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,5]]}}}